COVID-19 does not impact on outcome of myeloma patients infected while undergoing autologous stem cell transplantation.
Lorenzo MasinaNicola BianchettiAngela PassiChiara BottelliSamuele BagnascoAngelica SpolzinoMargherita ObertiMarco ChiariniAngelo BelottiSimone VoltoliniLaura FaglioniGiuseppe RossiAlessandra TucciChiara CattaneoPublished in: Hematological oncology (2023)
Here we report two cases of myeloma patients who became positive for SARS-CoV-2 infection during the acute phase of autologous stem cell transplant. Both patients were promptly treated with monoclonal antibodies and remdesivir, and, despite the profound neutropenia and lymphopenia, they did not develop respiratory failure and they remained paucisymptomatic during the entire period of aplasia. Neutrophil engraftment took place as expected and the patients were discharged quickly and did not experience adverse effects after discharge.
Keyphrases
- newly diagnosed
- end stage renal disease
- stem cell transplantation
- stem cells
- ejection fraction
- prognostic factors
- coronavirus disease
- patient reported outcomes
- low dose
- autism spectrum disorder
- intensive care unit
- extracorporeal membrane oxygenation
- cell therapy
- acute respiratory distress syndrome
- mechanical ventilation
- platelet rich plasma
- cord blood